Naloxone Hydrochloride Injection, USP

Manufacturer
Mylan Institutional LLC
Effective date
2024-04-12
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
full-release
Hydrated at
2026-05-31 22:19:26

Label at a glance#

ProductNaloxone Hydrochloride
Active ingredientNALOXONE HYDROCHLORIDE
Label structure14 sections

Indications and uses

Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. Naloxone hydrochloride injection is also indicated for diagnosis of suspected or known acute opioi...

Dosage and administration

Naloxone hydrochloride injection may be administered intravenously, intramuscularly, or subcutaneously. The most rapid onset of action is achieved by intravenous administration, which is recommended in emergency situations. Since the duration of action of some opioids may exceed that of naloxone hydrochloride injection, the patient should be kept under continued surveillance. Repeated doses of naloxone hydrochlori...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Naloxone hydrochloride injection, USP, an opioid antagonist, is a synthetic congener of oxymorphone. In structure it differs from oxymorphone in that the methyl group on the nitrogen atom is replaced by an allyl group.

Naloxone Hydrochloride Dihydrate Structural Formula
Naloxone Hydrochloride Dihydrate Structural Formula

Naloxone hydrochloride, USP occurs as a white to slightly off-white powder, and is soluble in water, in dilute acids, and in strong alkali; slightly soluble in alcohol; practically insoluble in ether and in chloroform.

Naloxone hydrochloride injection, USP is available as a sterile, clear, colorless solution for intravenous, intramuscular and subcutaneous administration in 1 mg of naloxone hydrochloride USP per mL concentration.

pH is adjusted to 3.5 ± 0.5 with hydrochloric acid.

Each mL also contains 9 mg of sodium chloride. Naloxone hydrochloride injection, USP is available as an unpreserved, paraben-free formulation.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Complete or Partial Reversal of Opioid Depression

SPL UNCLASSIFIED SECTION

Naloxone hydrochloride prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension. Also, naloxone hydrochloride can reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.

Naloxone hydrochloride is an essentially pure opioid antagonist, i.e., it does not possess the “agonistic” or morphine-like properties characteristic of other opioid antagonists. When administered in usual doses and in the absence of opioids or agonistic effects of other opioid antagonists, it exhibits essentially no pharmacologic activity.

Naloxone hydrochloride has not been shown to produce tolerance or cause physical or psychological dependence. In the presence of physical dependence on opioids, naloxone hydrochloride will produce withdrawal symptoms. However, in the presence of opioid dependence, opiate withdrawal symptoms may appear within minutes of naloxone hydrochloride administration and subside in about 2 hours. The severity and duration of the withdrawal syndrome are related to the dose of naloxone hydrochloride and to the degree and type of opioid dependence. While the mechanism of action of naloxone hydrochloride is not fully understood, in vitro evidence suggests that naloxone hydrochloride antagonizes opioid effects by competing for the µ, κ and σ opiate receptor sites in the CNS, with the greatest affinity for the µ receptor.

When naloxone hydrochloride is administered intravenously (I.V.), the onset of action is generally apparent within two minutes. The onset of action is slightly less rapid when it is administered subcutaneously (S.C.) or intramuscularly (I.M.). The duration of action is dependent upon the dose and route of administration of naloxone hydrochloride. Intramuscular administration produces a more prolonged effect than intravenous administration. Since the duration of action of naloxone hydrochloride may be shorter than that of some opiates, the effects of the opiate may return as the effects of naloxone hydrochloride dissipates. The requirement for repeat doses of naloxone hydrochloride will also be dependent upon the amount, type and route of administration of the opioid being antagonized.

Adjunctive Use in Septic Shock

SPL UNCLASSIFIED SECTION

Naloxone hydrochloride has been shown in some cases of septic shock to produce a rise in blood pressure that may last up to several hours; however, this pressor response has not been demonstrated to improve patient survival. In some studies, treatment with naloxone hydrochloride in the setting of septic shock has been associated with adverse effects, including agitation, nausea and vomiting, pulmonary edema, hypotension, cardiac arrhythmias, and seizures. The decision to use naloxone hydrochloride in septic shock should be exercised with caution, particularly in patients who may have underlying pain or have previously received opioid therapy and may have developed opioid tolerance.

Because of the limited number of patients who have been treated, optimal dosage and treatment regimens have not been established.

PHARMACOKINETICS

PHARMACOKINETICS SECTION

Distribution

SPL UNCLASSIFIED SECTION

Following parenteral administration, naloxone hydrochloride is rapidly distributed in the body and readily crosses the placenta. Plasma protein binding occurs but is relatively weak. Plasma albumin is the major binding constituent but significant binding of naloxone also occurs to plasma constituents other than albumin. It is not known whether naloxone is excreted into human milk.

Metabolism and Elimination

SPL UNCLASSIFIED SECTION

Naloxone hydrochloride is metabolized in the liver, primarily by glucuronide conjugation with naloxone-3-glucoronide as the major metabolite. In one study the serum half-life in adults ranged from 30 to 81 minutes (mean 64 ± 12 minutes). In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours. After an oral or intravenous dose, about 25 to 40% of the drug is excreted as metabolites in urine within 6 hours, about 50% in 24 hours, and 60 to 70% in 72 hours.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. Naloxone hydrochloride injection is also indicated for diagnosis of suspected or known acute opioid overdosage.

Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY; Adjunctive Use in Septic Shock).

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients in naloxone hydrochloride.

WARNINGS

WARNINGS SECTION

Drug Dependence

SPL UNCLASSIFIED SECTION

Naloxone hydrochloride should be administered cautiously to persons including newborns of mothers who are known or suspected to be physically dependent on opioids. In such cases an abrupt and complete reversal of opioid effects may precipitate an acute withdrawal syndrome.

The signs and symptoms of opioid withdrawal in a patient physically dependent on opioids may include, but are not limited to, the following: body aches, diarrhea, tachycardia, fever, runny nose, sneezing, piloerection, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure. In the neonate, opioid withdrawal may also include: convulsions, excessive crying, and hyperactive reflexes.

Repeat Administration

SPL UNCLASSIFIED SECTION

The patient who has satisfactorily responded to naloxone hydrochloride should be kept under continued surveillance and repeated doses of naloxone hydrochloride should be administered, as necessary, since the duration of action of some opioids may exceed that of naloxone hydrochloride.

Respiratory Depression due to Other Drugs

SPL UNCLASSIFIED SECTION

Naloxone hydrochloride is not effective against respiratory depression due to non-opioid drugs and in the management of acute toxicity caused by levopropoxyphene. Reversal of respiratory depression by partial agonists or mixed agonist/antagonists, such as buprenorphine and pentazocine, may be incomplete or require higher doses of naloxone. If an incomplete response occurs, respirations should be mechanically assisted as clinically indicated.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

In addition to naloxone hydrochloride, other resuscitative measures such as maintenance of a free airway, artificial ventilation, cardiac massage, and vasopressor agents should be available and employed when necessary to counteract acute opioid poisoning.

Abrupt postoperative reversal of opioid depression may result in nausea, vomiting, sweating, tremulousness, tachycardia, increased blood pressure, seizures, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest which may result in death. Excessive doses of naloxone hydrochloride in postoperative patients may result in significant reversal of analgesia and may cause agitation (see PRECAUTIONS and DOSAGE AND ADMINISTRATION; Usage in Adults-Postoperative Opioid Depression). Several instances of hypotension, hypertension, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest have been reported in postoperative patients. Death, coma, and encephalopathy have been reported as sequelae of these events. These have occurred in patients most of whom had pre-existing cardiovascular disorders or received other drugs which may have similar adverse cardiovascular effects. Although a direct cause and effect relationship has not been established, naloxone hydrochloride should be used with caution in patients with pre-existing cardiac disease or patients who have received medications with potential adverse cardiovascular effects, such as hypotension, ventricular tachycardia or fibrillation, and pulmonary edema. It has been suggested that the pathogenesis of pulmonary edema associated with the use of naloxone hydrochloride is similar to neurogenic pulmonary edema, i.e., a centrally mediated massive catecholamine response leading to a dramatic shift of blood volume into the pulmonary vascular bed resulting in increased hydrostatic pressures.

Drug Interactions

DRUG INTERACTIONS SECTION

Large doses of naloxone are required to antagonize buprenorphine since the latter has a long duration of action due to its slow rate of binding and subsequent slow dissociation from the opioid receptor. Buprenorphine antagonism is characterized by a gradual onset of the reversal effects and a decreased duration of action of the normally prolonged respiratory depression. The barbiturate methohexital appears to block the acute onset of withdrawal symptoms induced by naloxone in opiate addicts.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Studies in animals to assess the carcinogenic potential of naloxone hydrochloride have not been conducted. Naloxone hydrochloride was weakly positive in the Ames mutagenicity and in the in vitro human lymphocyte chromosome aberration test but was negative in the in vitro Chinese hamster V79 cell HGPRT mutagenicity assay and in the in vivo rat bone marrow chromosome aberration study. Reproduction studies conducted in mice and rats at doses 4-times and 8-times, respectively, the dose of a 50 kg human given 10 mg/day (when based on surface area or mg/m2), demonstrated no embryotoxic or teratogenic effects due to naloxone hydrochloride.

Use in Pregnancy

SPL UNCLASSIFIED SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Teratology studies conducted in mice and rats at doses 4-times and 8-times, respectively, the dose of a 50 kg human given 10 mg/day (when based on surface area or mg/m2), demonstrated no embryotoxic or teratogenic effects due to naloxone hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, naloxone hydrochloride should be used during pregnancy only if clearly needed.

Non-teratogenic Effects

NONTERATOGENIC EFFECTS SECTION

Risk-benefit must be considered before naloxone hydrochloride is administered to a pregnant woman who is known or suspected to be opioid-dependent since maternal dependence may often be accompanied by fetal dependence. Naloxone crosses the placenta, and may precipitate withdrawal in the fetus as well as in the mother. Patients with mild to moderate hypertension who receive naloxone during labor should be carefully monitored as severe hypertension may occur.

Use in Labor and Delivery

SPL UNCLASSIFIED SECTION

It is not known if naloxone hydrochloride injection affects the duration of labor and/or delivery. However, published reports indicated that administration of naloxone during labor did not adversely affect maternal or neonatal status.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether naloxone hydrochloride is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when naloxone hydrochloride is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Naloxone hydrochloride injection may be administered intravenously, intramuscularly or subcutaneously in children and neonates to reverse the effects of opiates. The American Academy of Pediatrics, however, does not endorse subcutaneous or intramuscular administration in opiate intoxication since absorption may be erratic or delayed. Although the opiate-intoxicated child responds dramatically to naloxone hydrochloride, he/she must be carefully monitored for at least 24 hours as a relapse may occur as naloxone is metabolized.

When naloxone hydrochloride is given to the mother shortly before delivery, the duration of its effect lasts only for the first two hours of neonatal life. It is preferable to administer naloxone hydrochloride directly to the neonate if needed after delivery. Naloxone hydrochloride has no apparent benefit as an additional method of resuscitation in the newly born infant with intrauterine asphyxia which is not related to opioid use.

Usage in Pediatric Patients and Neonates for Septic Shock:

The safety and effectiveness of naloxone hydrochloride in the treatment of hypotension in pediatric patients and neonates with septic shock have not been established. One study of two neonates in septic shock reported a positive pressor response; however, one patient subsequently died after intractable seizures.

Geriatric Use

GERIATRIC USE SECTION

Clinical studies of naloxone hydrochloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Renal Insufficiency/Failure

SPL UNCLASSIFIED SECTION

The safety and effectiveness of naloxone hydrochloride in patients with renal insufficiency/failure have not been established in well-controlled clinical trials. Caution should be exercised when naloxone hydrochloride is administered to this patient population.

Liver Disease

SPL UNCLASSIFIED SECTION

The safety and effectiveness of naloxone hydrochloride in patients with liver disease have not been established in well-controlled clinical trials. Caution should be exercised when naloxone hydrochloride is administered to patients with liver disease.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Postoperative

SPL UNCLASSIFIED SECTION

The following adverse events have been associated with the use of naloxone hydrochloride in postoperative patients: hypotension, hypertension, ventricular tachycardia and fibrillation, dyspnea, pulmonary edema, and cardiac arrest. Death, coma, and encephalopathy have been reported as sequelae of these events. Excessive doses of naloxone hydrochloride in postoperative patients may result in significant reversal of analgesia and may cause agitation (see PRECAUTIONS and DOSAGE AND ADMINISTRATION; Usage in Adults-Postoperative Opioid Depression).

Opioid Depression

SPL UNCLASSIFIED SECTION

Abrupt reversal of opioid depression may result in nausea, vomiting, sweating, tachycardia, increased blood pressure, tremulousness, seizures, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest which may result in death (see PRECAUTIONS). 

Opioid Dependence

SPL UNCLASSIFIED SECTION

Abrupt reversal of opioid effects in persons who are physically dependent on opioids may precipitate an acute withdrawal syndrome which may include, but is not limited to, the following signs and symptoms: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, tachycardia. In the neonate, opioid withdrawal may also include: convulsions; excessive crying; hyperactive reflexes (see WARNINGS).

Adverse events associated with the postoperative use of naloxone hydrochloride are listed by organ system and in decreasing order of frequency as follows:

Cardiac Disorders: pulmonary edema, cardiac arrest or failure, tachycardia, ventricular fibrillation, and ventricular tachycardia. Death, coma, and encephalopathy have been reported as sequelae of these events.

Gastrointestinal Disorders: vomiting, nausea

Nervous System Disorders: convulsions, paraesthesia, grand mal convulsion

Psychiatric Disorders: agitation, hallucination, tremulousness

Respiratory, Thoracic and Mediastinal Disorders: dyspnea, respiratory depression, hypoxia

Skin and Subcutaneous Tissue Disorders: nonspecific injection site reactions, sweating

Vascular Disorders: hypertension, hypotension, hot flushes or flushing.

See also PRECAUTIONS and DOSAGE AND ADMINISTRATION; Usage in Adults; Postoperative Opioid Depression.

To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.)

DRUG ABUSE AND DEPENDENCE

DRUG ABUSE AND DEPENDENCE SECTION

Naloxone hydrochloride is an opioid antagonist. Physical dependence associated with the use of naloxone hydrochloride has not been reported. Tolerance to the opioid antagonist effect naloxone hydrochloride is not known to occur.

OVERDOSAGE

OVERDOSAGE SECTION

There is limited clinical experience with naloxone hydrochloride overdosage in humans.

Adult Patients

SPL UNCLASSIFIED SECTION

In one small study, volunteers who received 24 mg/70 kg did not demonstrate toxicity. In another study, 36 patients with acute stroke received a loading dose of 4 mg/kg (10 mg/m2/min) of naloxone hydrochloride followed immediately by 2 mg/kg/hr for 24 hours. Twenty-three patients experienced adverse events associated with naloxone use, and naloxone was discontinued in seven patients because of adverse effects. The most serious adverse events were: seizures (2 patients), severe hypertension (1), and hypotension and/or bradycardia (3).

At doses of 2 mg/kg in normal subjects, cognitive impairment and behavioral symptoms, including irritability, anxiety, tension, suspiciousness, sadness, difficulty concentrating, and lack of appetite have been reported. In addition, somatic symptoms, including dizziness, heaviness, sweating, nausea, and stomachaches were also reported. Although complete information is not available, behavioral symptoms were reported to often persist for 2 to 3 days.

Pediatric Patients

SPL UNCLASSIFIED SECTION

Up to 11 doses of 0.2 mg of naloxone (2.2 mg) have been administered to children following overdose of diphenoxylate hydrochloride with atropine sulfate. Pediatric reports include a 2½ year-old child who inadvertently received a dose of 20 mg of naloxone for treatment of respiratory depression following overdose with diphenoxylate hydrochloride with atropine sulfate. The child responded well and recovered without adverse sequelae. There is also a report of a 4½ year-old child who received 11 doses during a 12-hour period, with no adverse sequelae.

Patient Management

SPL UNCLASSIFIED SECTION

Patients who experience a naloxone hydrochloride overdose should be treated symptomatically in a closely supervised environment. Physicians should contact a poison control center for the most up-to-date patient management information.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Naloxone hydrochloride injection may be administered intravenously, intramuscularly, or subcutaneously. The most rapid onset of action is achieved by intravenous administration, which is recommended in emergency situations.

Since the duration of action of some opioids may exceed that of naloxone hydrochloride injection, the patient should be kept under continued surveillance. Repeated doses of naloxone hydrochloride injection should be administered, as necessary. Naloxone hydrochloride injection is a single-dose, prefilled syringe. Discard unused portion.

Intravenous Infusion

SPL UNCLASSIFIED SECTION

Naloxone hydrochloride injection may be diluted for intravenous infusion in normal saline or 5% dextrose solutions. The addition of 2 mg of naloxone hydrochloride injection in 500 mL of either solution provides a concentration of 0.004 mg/mL. Mixtures should be used within 24 hours. After 24 hours, the remaining unused mixture must be discarded. The rate of administration should be titrated in accordance with the patient’s response.

Naloxone hydrochloride injection should not be mixed with preparations containing bisulfite, metabisulfite, long-chain or high molecular weight anions, or any solution having an alkaline pH. No drug or chemical agent should be added to naloxone hydrochloride injection unless its effect on the chemical and physical stability of the solution has first been established.

General

GENERAL PRECAUTIONS SECTION

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Usage in Adults

SPL UNCLASSIFIED SECTION

Opioid Overdose–Known or Suspected

SPL UNCLASSIFIED SECTION

An initial dose of 0.4 mg to 2 mg of naloxone hydrochloride injection may be administered intravenously. If the desired degree of counteraction and improvement in respiratory functions are not obtained, it may be repeated at two- to three-minute intervals. If no response is observed after 10 mg of naloxone hydrochloride injection have been administered, the diagnosis of opioid-induced or partial opioid-induced toxicity should be questioned. Intramuscular or subcutaneous administration may be necessary if the intravenous route is not available.

Postoperative Opioid Depression

SPL UNCLASSIFIED SECTION

For the partial reversal of opioid depression following the use of opioids during surgery, smaller doses of naloxone hydrochloride injection are usually sufficient. The dose of naloxone hydrochloride injection should be titrated according to the patient’s response. For the initial reversal of respiratory depression, naloxone hydrochloride injection should be injected in increments of 0.1 mg to 0.2 mg intravenously at two- to three-minute intervals to the desired degree of reversal, i.e., adequate ventilation and alertness without significant pain or discomfort. Larger than necessary dosage of naloxone hydrochloride injection may result in significant reversal of analgesia and increase in blood pressure. Similarly, too rapid reversal may induce nausea, vomiting, sweating or circulatory stress.

Repeat doses of naloxone hydrochloride injection may be required within one- to two-hour intervals depending upon the amount, type (i.e., short or long acting) and time interval since last administration of an opioid. Supplemental intramuscular doses have been shown to produce a longer lasting effect.

Septic Shock

SPL UNCLASSIFIED SECTION

The optimal dosage of naloxone hydrochloride injection or duration of therapy for the treatment of hypotension in septic shock patients has not been established (see CLINICAL PHARMACOLOGY).

Usage in Children

SPL UNCLASSIFIED SECTION

Opioid Overdose–Known or Suspected:

The usual initial dose in children is 0.01 mg/kg body weight given I.V. If this dose does not result in the desired degree of clinical improvement, a subsequent dose of 0.1 mg/kg body weight may be administered. If an I.V. route of administration is not available, naloxone hydrochloride injection may be administered I.M. or S.C. in divided doses. If necessary, naloxone hydrochloride injection can be diluted with sterile water for injection.

Postoperative Opioid Depression:

Follow the recommendations and cautions under Adult Postoperative Depression. For the initial reversal of respiratory depression, naloxone hydrochloride injection should be injected in increments of 0.005 mg to 0.01 mg intravenously at two- to three-minute intervals to the desired degree of reversal.

Usage in Neonates

SPL UNCLASSIFIED SECTION

Opioid-induced Depression:

The usual initial dose is 0.01 mg/kg body weight administered I.V., I.M. or S.C. This dose may be repeated in accordance with adult administration guidelines for postoperative opioid depression.

HOW SUPPLIED

HOW SUPPLIED SECTION

Naloxone hydrochloride injection, USP is supplied as a kit containing a 2 mL single-dose prefilled syringe with luer lock adaptor and rigid tip cap, and a 21-gauge, 1½ inch needle with needle-stick protection device.

Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL)

One 2 mL Single-Dose Prefilled Syringe,

Packaged in a Carton with 1 Needle NDC-67457-992-02

Store at 25ºC (77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF). [See USP Controlled Room Temperature.] Protect from light.

Store in carton until contents have been used.

INSTRUCTIONS FOR USE

INSTRUCTIONS FOR USE SECTION

Prefilled Syringe
Prefilled Syringe
  1. Hold the syringe upright, remove the threaded plastic rigid tip cap with an easy anti-clockwise twisting motion.
Step 1
Step 1
  1. Peel the safety needle pouch half way open. Grasp the needle sheath using the plastic peel pouch. Attach the safety needle to the luer connection of the syringe with an easy clockwise twisting motion.
Step 2
Step 2
  1. Pull the needle sheath away from the needle with a straight pull. Do not twist the sheath as the needle may be loosened from the syringe.
Step 3
Step 3
  1. Bring the syringe with the attached needle in upright position to de-aerate. De-aerate the syringe by moving the plunger rod carefully forward.
Step 4
Step 4
  1. After the injection is complete, use either thumb or finger of one hand or a flat surface to activate the needle protection system. The needle protection system is fully activated when a ‘click’ is heard. Discard the syringe with needle appropriately.
Step 5
Step 5

Manufactured for:
Mylan Institutional LLC
Morgantown, WV 26505 U.S.A.

Manufactured by:
Mylan Laboratories Limited
Bangalore, India

APRIL 2024

PRINCIPAL DISPLAY PANEL -2 mg/2 mL (1 mg/mL)

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 67457-992-02

Naloxone Hydrochloride
Injection, USP

2 mg/2 mL (1 mg/mL)

For Intravenous, Intramuscular or
Subcutaneous Use / An Opioid Antagonist
Single Dose, do not reuse or resterilize.

Sterile
Rx only

Each Carton Contains:
One 2 mL Single-Dose Prefilled Syringe.
One 21-Gauge, 1½ Inch Needle.

2 mL Single-Dose Disposable Prefilled Syringe

Each mL contains naloxone hydrochloride, USP, 1 mg; and sodium chloride, 9 mg, pH adjusted with hydrochloric acid to meet USP limits of 3.5 ± 0.5.

Medication and fluid pathway sterile and nonpyrogenic in original, unopened package, with component cap in place.
Do not remove cap until ready to use.

Single Dose/No Preservative added/Protect from light. Discard unused portion.

Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).
[See USP Controlled Room Temperature.]/Usual Dosage: See Insert.

INSTRUCTIONS FOR USE

  1. Hold the syringe upright,
    remove the threaded
    plastic rigid tip cap with
    an easy anti-clockwise
    twisting motion.
Step 1Step 1
  1. Peel the safety needle
    pouch half way open.
    Grasp the needle sheath
    using the plastic peel
    pouch. Attach the safety
    needle to the luer
    connection of the syringe
    with an easy clockwise
    twisting motion.
Step 2Step 2
  1. Pull the needle sheath
    away from the needle with
    a straight pull. Do not twist
    the sheath as the needle
    may be loosened from the syringe.
Step 3Step 3
  1. Bring the syringe with the
    attached needle in upright
    position to de-aerate.
    De-aerate the syringe by
    moving the plunger rod
    carefully forward.
Step 4Step 4
  1. After the injection
    is complete, use
    either thumb or
    finger of one hand
    or a flat surface
    to activate the
    needle protection
    system. The
    needle protection
    system is fully
    activated when
    a ‘click’ is heard.
    Discard the
    syringe with
    needle
    appropriately.
Step 5Step 5

Manufactured for:
Mylan Institutional LLC
Morgantown, WV 26505 U.S.A.

Made in India

Code No.: KR/DRUGS/KTK/28/384/2009

2 mg/2 mL (1 mg/mL) Carton Label
2 mg/2 mL (1 mg/mL) Carton Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1191250naloxone HCl 2 MG in 2 ML Prefilled SyringePSN4
11912502 ML naloxone hydrochloride 1 MG/ML Prefilled SyringeSCD4
1191250naloxone hydrochloride 2 MG per 2 ML Prefilled SyringeSY4

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
NALOXONE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130367457992020GTIN-13: 0367457992020
EAN-13: 0367457992020
GTIN-12: 367457992020
UPC-A: 367457992020
GTIN storage (14 digits): 00367457992020
image-13.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
c955d208-c333-9bd7-be34-d7e12986d44eProduct name620250626
e5f98bfa-66d5-4c3a-b22d-9543d3bee304Product name120250204
caa6391e-3db3-c912-335f-61b5fc00aa12Product name920240110
65a3bc34-04ff-4cf1-aad9-c7d92a062f6dProduct name120231003
e951cdf3-f269-4d97-a7d5-c1c3d7283a7dProduct name320230313
ab841ac7-728a-4fc9-be0a-35b96cecbf39Product name420230306
f327b80c-8fa2-404b-838a-df3eec141cf2Product name120221212
d4aa2fcf-79c3-4b5f-a00e-1a8e26e00119Product name120220511
b871fccd-1de6-4c7f-b9e5-045304641ee6Product name820220118
43b1efe2-1425-4b3e-b3a2-57d40f8478b9Product name120211026
4c23a34c-e8fc-424c-8fa0-ee064ba6eaefProduct name120170706
0b8c7273-1da3-495f-909a-7cf1e96d2361Product name120161212
3df867ed-9d48-45cf-bded-1394beaea0b1Product name320161206
8a245632-e24f-4ccc-b671-995d89c96ebcProduct name120141203

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
67457-992-02Naloxone Hydrochloride2 mL in 1 SYRINGE, GLASSINJECTION, SOLUTION24
67457-992-02Naloxone Hydrochloride1 in 1 CARTONINJECTION, SOLUTION14

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
67457-992-02ML - Milliliter67457-9921d9f0fa5-96a9-4d56-9301-f0c1e4e2c79912023-01-09

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
67457-99267457-992-02

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Name, UNII, Kind table
NameUNIIKind
NALOXONE HYDROCHLORIDEF850569PQRACTIM
SODIUM CHLORIDE451W47IQ8XIACT

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
32024-04-12monthly-update2026-06-03 17:47:41

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A213843-001NALOXONE HYDROCHLORIDENALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A213843-001AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09d4dbc9d85df4…
2026-10-15 13:18:302026-09A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09c2088c7a36db…
2026-09-14 22:38:342026-08A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-0984e616aacf4f…
2026-08-18 06:07:402026-07A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-0931067a03dcf5…
2025-08-23 18:47 UTC2025-08A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-096a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-0903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-092680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-095bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-0979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-091e350fbaab3a…
2024-05-31 18:47 UTC2024-05A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-098072bd15b7f6…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-096a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-091c564ffb4f44…
2023-12-20 04:57 UTC2023-12A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-099b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-093f0d92c62455…
2023-05-13 08:27 UTC2023-05A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09053a50430f4f…
2023-01-26 05:58 UTC2023-01A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-093bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-093a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A213843-001NALOXONE HYDROCHLORIDE1MG/MLINJECTABLE / INJECTIONAP2022-06-09a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A213843-001AP1d4dbc9d85df4…
2026-10-15 13:18:302026-09A213843-001AP1c2088c7a36db…
2026-09-14 22:38:342026-08A213843-001AP184e616aacf4f…
2026-08-18 06:07:402026-07A213843-001AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A213843-001AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A213843-001AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08A213843-001AP16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A213843-001AP1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A213843-001AP1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A213843-001AP103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A213843-001AP12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A213843-001AP15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A213843-001AP1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A213843-001AP1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A213843-001AP179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A213843-001AP1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A213843-001AP11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A213843-001AP18072bd15b7f6…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A213843-001AP16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A213843-001AP11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A213843-001AP1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A213843-001AP1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A213843-001AP19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A213843-001AP1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A213843-001AP13f0d92c62455…
2023-05-13 08:27 UTC2023-05A213843-001AP1053a50430f4f…
2023-01-26 05:58 UTC2023-01A213843-001AP13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A213843-001AP13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A213843-001AP1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A213843-001AP1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A213843-001AP1cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A213843-001AP1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Naloxone HydrochlorideNALOXONE HYDROCHLORIDEMylan Institutional LLC7faaedb3-227b-408d-b772-6b326638b00e2024-04-12Warnings, Adverse reactionsExact identifier
ndc (package): 67457-992-02
ndc (product): 67457-992
ndc11 (package): 67457099202
spl id: f7011032-c1aa-406a-9070-e1d3749fa9bf
spl set id: 7faaedb3-227b-408d-b772-6b326638b00e

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.